Emerging drugs for the treatment of moderately to severely active ulcerative colitis: review of phase II and III clinical trials.

Laura NeurathFerdinando D'AmicoSilvio Danese

Published in: Expert opinion on emerging drugs (2023)

We highlight the potential impact of these agents for the future therapeutic landscape of this disease with special emphasis on clinical impact, unmet needs, safety aspects, and advanced combination therapy.

Keyphrases

combination therapy
phase ii
clinical trial
ulcerative colitis
open label
phase iii
double blind
placebo controlled
current status
randomized controlled trial
study protocol
single cell
replacement therapy
climate change